Patents Assigned to PROLYNX LLC
-
Publication number: 20240082436Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.Type: ApplicationFiled: July 11, 2023Publication date: March 14, 2024Applicant: ProLynx LLCInventors: Daniel V. SANTI, Shaun FONTAINE
-
Publication number: 20240041982Abstract: Provided herein are extended release hydrogel conjugates of c-natriuretic peptides, methods of preparation thereof, and methods of use thereof.Type: ApplicationFiled: November 24, 2021Publication date: February 8, 2024Applicant: ProLynx LLCInventors: Eric L. SCHNEIDER, Brian R. HEARN, Daniel V. SANTI
-
Publication number: 20230321286Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.Type: ApplicationFiled: March 7, 2023Publication date: October 12, 2023Applicant: ProLynx LLCInventors: Brian HEARN, Daniel V. SANTI, Shaun FONTAINE, Gary W. ASHLEY
-
Patent number: 11730836Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.Type: GrantFiled: January 11, 2019Date of Patent: August 22, 2023Assignee: ProLynx LLCInventors: Daniel V. Santi, Shaun Fontaine
-
Publication number: 20230135347Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.Type: ApplicationFiled: September 7, 2022Publication date: May 4, 2023Applicant: ProLynx LLCInventors: Gary W. ASHLEY, Daniel V. SANTI, Jeffrey C. HENISE
-
Publication number: 20220331437Abstract: Provided herein are releasable conjugates of inhibitors of DNA damage response suitable for use as therapeutic agents in the treatment of disease.Type: ApplicationFiled: August 28, 2020Publication date: October 20, 2022Applicant: ProLynx LLCInventors: Shaun D. FONTAINE, Brian R. HEARN, Daniel V. SANTI
-
Patent number: 11454861Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.Type: GrantFiled: August 30, 2019Date of Patent: September 27, 2022Assignee: ProLynx LLCInventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
-
Publication number: 20220280654Abstract: Provided are ?-eliminative linkers suitable for the conjugation of small molecule, peptide, and protein and compounds comprising the linkers.Type: ApplicationFiled: April 3, 2020Publication date: September 8, 2022Applicant: ProLynx LLCInventors: Gary W. ASHLEY, Brian HEARN, Shaun FONTAINE, Eric L. SCHNEIDER
-
Publication number: 20220265873Abstract: Methods for the steam sterilization of hydrogels crosslinked with a beta-eliminative linker without the drawback of significant degradation are provided.Type: ApplicationFiled: August 7, 2020Publication date: August 25, 2022Applicant: ProLynx LLCInventors: Jeffrey C. HENISE, Gary W. ASHLEY, Brian YAO
-
Publication number: 20220193253Abstract: This disclosure generally relates to releasable cytokine conjugates and methods of using the same.Type: ApplicationFiled: April 24, 2020Publication date: June 23, 2022Applicant: ProLynx LLCInventors: John A. HANGASKY, III, Samuel J. PFAFF, Daniel V. SANTI
-
Patent number: 11181803Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.Type: GrantFiled: January 15, 2019Date of Patent: November 23, 2021Assignee: ProLynx LLCInventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
-
Patent number: 11179470Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.Type: GrantFiled: January 15, 2019Date of Patent: November 23, 2021Assignee: ProLynx LLCInventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
-
Publication number: 20200397778Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.Type: ApplicationFiled: January 11, 2019Publication date: December 24, 2020Applicant: ProLynx LLCInventors: Daniel V. SANTI, Shaun FONTAINE
-
Publication number: 20200360545Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.Type: ApplicationFiled: January 11, 2019Publication date: November 19, 2020Applicant: ProLynx LLCInventors: Brian HEARN, Daniel V. SANTI, Shaun FONTAINE, Gary W. ASHLEY
-
Publication number: 20200164083Abstract: Extended-release conjugates of stabilized GLP-1 agonists balance agonist stability with release rates to provide long lasting administration to treat diabetes and related conditions on once-a-month or less frequent dosing schedules.Type: ApplicationFiled: March 16, 2017Publication date: May 28, 2020Applicant: ProLynx LLCInventors: Eric L. SCHNEIDER, Brian HEARN, Jeffrey C. HENISE, Gary W. ASHLEY, Daniel V. SANTI
-
Publication number: 20200054756Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.Type: ApplicationFiled: August 30, 2019Publication date: February 20, 2020Applicant: ProLynx LLCInventors: Gary W. ASHLEY, Daniel V. SANTI, Jeffrey C. HENISE
-
Patent number: 10413594Abstract: Conjugates of carriers and hydrogels for controlling the biological half-life of somatostatin and its analogs are disclosed.Type: GrantFiled: June 22, 2018Date of Patent: September 17, 2019Assignee: ProLynx LLCInventors: Eric L. Schneider, Brian Hearn, Gary W. Ashley, Daniel V. Santi
-
Patent number: 10398779Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.Type: GrantFiled: April 12, 2017Date of Patent: September 3, 2019Assignee: ProLynx LLCInventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
-
Publication number: 20190209692Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.Type: ApplicationFiled: January 15, 2019Publication date: July 11, 2019Applicant: ProLynx LLCInventors: Gary W. ASHLEY, Daniel V. SANTI, Jeffrey C. HENISE
-
Publication number: 20190209691Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.Type: ApplicationFiled: January 15, 2019Publication date: July 11, 2019Applicant: ProLynx LLCInventors: Gary W. ASHLEY, Daniel V. SANTI, Jeffrey C. HENISE
